Publication:
Differences in maternal and neonatal cardiometabolic markers and placenta status by foetal sex. The GESTAFIT project.

dc.contributor.authorAparicio, Virginia A
dc.contributor.authorBaena-García, Laura
dc.contributor.authorFlor-Alemany, Marta
dc.contributor.authorMartínez-González, Luis J
dc.contributor.authorVarela-López, Alfonso
dc.contributor.authorSánchez, Cristina
dc.contributor.authorQuiles, José L
dc.date.accessioned2023-05-03T13:32:32Z
dc.date.available2023-05-03T13:32:32Z
dc.date.issued2022
dc.description.abstractTo explore the differences in some maternal-neonatal metabolic markers and placenta status by foetal sex. One hundred thirty-nine Caucasian pregnant women from the GESTAFIT project and their new-borns were included in the present cross-sectional study. Serum cardiometabolic markers (i.e. lipid and glycaemic profile and uric acid) were analysed at late pregnancy and at birth. In placenta, telomeres length, proportion of deleted mitochondrial-DNA and mitochondrial-DNA density, some minerals and interleukin 8, epidermal growth factor, fibroblast growth factor-2 and vascular endothelial growth factor were measured. The study was run between November 2015 and April 2018. Mothers carrying a male showed higher serum triglycerides than mothers carrying a female at late pregnancy (p  Our findings show weak differences in some cardiometabolic and placental status markers by foetal sex. Notwithstanding, we observed a slightly more proatherogenic profile in both, mothers carrying males' foetuses and male new-borns. We also found lower serum uric acid and better placenta status in mothers carrying a female. These findings indicate that foetal sex might need to be considered for a more personalized follow-up of pregnancies.
dc.identifier.doi10.1177/17455057221117976
dc.identifier.essn1745-5065
dc.identifier.pmcPMC9393354
dc.identifier.pmid35989614
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393354/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1177/17455057221117976
dc.identifier.urihttp://hdl.handle.net/10668/20227
dc.journal.titleWomen's health (London, England)
dc.journal.titleabbreviationWomens Health (Lond)
dc.language.isoen
dc.organizationCentro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica-GENYO
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.page.number1,7455057221118E+016
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectfibroblast Growth Factor
dc.subjectlipids
dc.subjectnewborn
dc.subjectpregnancy
dc.subjecttelomere
dc.subjecttriglycerides
dc.subject.meshBiomarkers
dc.subject.meshCardiovascular Diseases
dc.subject.meshCross-Sectional Studies
dc.subject.meshDNA
dc.subject.meshFemale
dc.subject.meshFibroblast Growth Factor 2
dc.subject.meshHumans
dc.subject.meshInfant, Newborn
dc.subject.meshMale
dc.subject.meshPlacenta
dc.subject.meshPregnancy
dc.subject.meshSex Factors
dc.subject.meshUric Acid
dc.subject.meshVascular Endothelial Growth Factor A
dc.titleDifferences in maternal and neonatal cardiometabolic markers and placenta status by foetal sex. The GESTAFIT project.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number18
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9393354.pdf
Size:
509.09 KB
Format:
Adobe Portable Document Format